Publications

INFECTIOUS DISEASES

HEMORRHAGIC FEVER VIRUS

A single immunization with a modified vaccinia Ankara vectored vaccine producing Sudan virus-like particles protects from lethal infection

Malherbe D, Domi A, Hauser MJ, Atyeo C, Fischinger S, Hyde MA, Williams JM, Alter G, Guirakhoo F and Bukreyev A

NPJ Vaccines; 2022 Jul 25;7(1):83

 

A Single Dose of Modified Vaccinia Ankara expressing Ebola Virus Like Particles Protects Nonhuman Primates from Lethal Ebola Virus Challenge

Domi A, Feldmann F, Basu R, McCurley N, Shifflett K, Emanuel J, Hellerstein MS, Guirakhoo F, Orlandi C, Flinko R, Lewis GK, Hanley PW, Feldmann H, Robinson HL, Marzi A

Scientific Reports; 2018 Jan 16;8(1):86

 

Modified Vaccinia Ankara vaccine expressing Marburg virus-like particles protects guinea pigs from lethal Marburg virus infection

Malherbe D, Domi A, Hauser MJ, Meyer M, Gunn BM, Alter G, Bukreyev A, Guirakhoo F

NPJ Vaccines; 2020 Sep 2;5(1):78

 

HIV

Immunogenicity of a novel Clade B HIV-1 vaccine combination: Results of phase 1 randomized placebo controlled trial of an HIV-1 GM-CSF-expressing DNA prime with a modified vaccinia Ankara vaccine boost in healthy HIV-1 uninfected adults

Buchbinder SP, Grunenberg NA, Sanchez BJ, Seaton KE, Ferrari G, Moody MA, Frahm N, Montefiori DC, Hay CM, Goepfert PA, Baden LR, Robinson HL, Yu X, Gilber PB, McElrath MJ, Huang Y, Tomaras GD, on behalf of the HIV Vaccine Trials Network (HVTN) 094 Study Group

PLoS One; 2017 Jul 20;12(7)

 

DNA/MVA Vaccination of HIV-1 Infected Participants with Viral Suppression on Antiretroviral Therapy, followed by Treatment Interruption: Elicitation of Immune Responses without Control of Re-Emergent Virus

Thompson M, Heath SL, Sweeton B, Williams K, Cunningham P, Keele BF, Sen S, Palmer BE, Chomont N, Xu Y, Basu R, Hellerstein MS, Kwa S, Robinson HL

PLoS One; 2016 Oct 6;11(10)

 

Specificity and 6-Month Durability of Immune Responses Induced by DNA and Recombinant Modified Vaccinia Ankara Vaccines Expressing HIV-1 Virus-Like Particles

Goepfert PA, Elizaga ML, Seaton K, Tomaras GD, Montefiori DC, Sato A, Hural J, DeRosa SC, Kalams SA, McElrath MJ, Keefer MC, Baden LR, Lama JR, Sanchez J, Mulligan MJ, Buchbinder SP, Hammer SM, Koblin BA, Pensiero M, Butler C, Moss B, and Robinson HL, HVTN 205 Study Group, and the National Institutes of Allergy and Infectious Diseases HIV Vaccines Trials Network

Journal of Infectious Diseases; 2014 Jul 1; 210(1);99-110

 

Phase 1 Safety and Immunogenicity Testing of DNA and Recombinant Modified Vaccinia Ankara Vaccines Expressing HIV-1 Virus-like Particles

Goepfert PA, Elizaga ML, Sato A, Qin L, Cardinali M, Hay CM, Hural J, DeRosa SC, DeFawe OD, Tomaras GD, Montefiori DC, Xu Y, Lai L, Kalams SA, Baden LR, Frey SE, Blattner WA, Wyatt LS, Moss B, Robinson HL; National Institute of Allergy and Infectious Diseases HIV Vaccine Trials Network

Journal of Infectious Diseases; 2011 Mar 1;203(5);610-9

 

Excellent safety and tolerability of the human immunodeficiency virus type 1 pGA2/JS2 plasmid DNA priming vector vaccine in HIV type 1 uninfected adults

Mulligan MJ, Russell ND, Celum C, Kahn J, Noonan E, Montefiori DC, Ferrari G, Weinhold KJ, Smith JM, Amara RR, Robinson HL, NIH/NIAID/DAIDS HIV Vaccine Trials Network

AIDS Research and Human Retroviruses; 2006 Jul;22(7):678-83

 

MPOX (MONKEYPOX)

Recombinant modified vaccinia virus Ankara provides durable protection against disease caused by an immunodeficiency virus as well as long-term immunity to an orthopoxvirus in a non-human primate

Earl PL, Americo JL, Wyatt LS, Eller LA, Montefiori DC, Byrum R, Piatak M, Lifson JD, Amara RR, Robinson HL, Huggins JW, Moss B

Virology; 2007 Sep 15; 366(1); 84-97

 

DNA/MVA HIV-1/AIDS Vaccine Elicits Long-Lived Vaccinia Virus-Specific Immunity and Confers Protection Against a Lethal Monkeypox Challenge

Nigama P, Earl PL, Americo JL, Sharmaa S, Wyatt LS, Edghill-Spanoc Y, Chennareddia LS, Silvera P, Moss B, Robinson HL, and Amara RR

Virology; 2007 Sep 15; 366(1);73-83

 

ZIKA

A Zika Vaccine Targeting NS1 Protein Protects Immunocompetent Adult Mice in a Lethal Challenge Model

Brault AC, Domi A, McDonald EM, Talmi-Frank D, McCurley N, Basu R, Robinson HL, Hellerstein M, Duggal NK, Bowen RA, Guirakhoo F

Scientific Reports; 2017 Nov 7;7(1):14769

ONCOLOGY

HEAD AND NECK CANCER

Broadening Activity of Checkpoint Blockade Agents by Intratumoral Nucleoside Cleavage

Rab R, Hong JS, Kinney BLC, Schmitt NC, Parker WB, Westbrook A, Bennion SK, Ford ML, Weitzel DH, Miliani de Marval PL, Sorscher EJ, Ehrhardt A

JCI Insight; Volume 11, Issue 10; 2026 May 22

 

Phase I/II Study of Intratumoral Ad/Purine Nucleoside Phosphorylase (Gedeptin) With Fludarabine Phosphate in Patients With Recurrent Head and Neck Cancer

Colevas AD, Pipas JM, Schmitt NC, Saba NF, Curry JM, Rosenthal E, Parker WB, Martinez Ramirez LF, Hong JS, Rab R, Steininger MM, Raymundo R, Raiden E, McKee KT, Sorscher EJ

JCO Oncology Advances: Volume 2, Number 1, November 17, 2025

 

Intratumoral generation of 2-fluoroadenine to treat solid malignancies of the head and neck

Bechbahani TE, Rosenthal EL, Parker WB, Sorscher EJ

Head & Neck; Clinical Review, 2019 Jun;41(6):1979-1983

 

Use of E. coli Purine Nucleoside Phosphorylase in the Treatment of Solid Tumors

Parker WB, Sorscher EJ

Current Pharmaceutical Design; Volume 23, Issue 45, 2017, 7003-7024

 

Phase I dose-escalating trial of Escherichia coli purine nucleoside phosphorylase and fludarabine gene therapy for advanced solid tumors

Rosenthal EL, Chung TK, Parker WB, Allan PW, Clemons L, Lowman D, Hong J, Hunt FR, Richman J, Conry RM, Mannion K, Carroll WR, Nabell L, Sorscher EJ

Annuals of Oncology; 2015 Jul;26(7):1481-7